Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RSV604 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| RSV604 | DRUG | - |
Inclusion Criteria: * Healthy male and female subjects, 18-50 years of age, in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening. * Vital signs within the following parameters: oral body temperature between 35...
RSV604 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in Phase 1 clinical development. The only completed trial evaluated its safety, tolerability, and pharmacokinetics after single and multiple intravenous doses in healthy subjects.
RSV604 is being developed by Novartis AG, which trades under the ticker NVS. The company sponsored a Phase 1 study of the drug in healthy volunteers in the United Kingdom.
RSV604 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and no active trials are currently listed.
RSV604 has one completed clinical trial, NCT00416442, titled 'Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.' This Phase 1 study enrolled 48 participants in the United Kingdom and was completed.
RSV604 is not FDA approved. It is an investigational drug in Phase 1 clinical development. The only completed trial was a Phase 1 study in healthy volunteers, and no approval has been granted.